A Randomised, Double-blind Placebo-controlled Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of MIV-711 in Knee Joint Osteoarthritis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2017
At a glance
- Drugs MIV 711 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Medivir AB
- 12 Jul 2017 This trial was completed in Bulgaria (end date: 2017-05-23), according to European Clinical Trials Database.
- 04 Jul 2017 The trial has been completed in Germany as per European Clinical Trials Database; global end date 23 may 2017.
- 28 Apr 2017 According to a Medivir AB media release, the company expects to present the data from the study in the third quarter of 2017.